Table 4.

Summary of HLA-A2 tetramer titrations in a subset of HLA-A2+ patients treated with the vaccine alone or in sequence with cyclophosphamide

PatientMesoA2(531-539)
Tyrosinase
Survival (mo)
PreVaccine 3PreVaccine 3
Tetramer titration (patients without cytoxan)
    41:601:601:101:107.9
    61:40>1:601:201:206.1
    71:201:401:101:201.7
Tetramer titration (patients given cytoxan)
    11:101:401:101:103.23
    41:20>1:401:201:207.73
    71:401:601:201:2013.07
    8>1:601:201:101:103.7
    9>1:60>1:601:201:2012.3
    101:60<1:601:101:102.6
  • NOTE: Patient PBL were labeled with HLA-A2 tetramers as described in Patients and Methods. The tetramer dilutions at which detectable tetramer staining was lost are shown.

    Abbreviations: Pre, prevaccine 1; vaccine 3, prevaccine 3.